

EMAIL: SFELDMAN@OLSHANLAW.COM  
DIRECT DIAL: 212.451.2234

June 10, 2021

**VIA EMAIL AND EDGAR**U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549Attention: Abby Adams and Tim Buchmiller  
Division of Corporation Finance,  
Office of Life SciencesRe: Alzamend Neuro, Inc.  
Registration Statement on Form S-1 (No. 333-255955)  
Registration Statement on Form 8-A (No. 001- )

Ladies and Gentlemen:

On behalf of Alzamend Neuro, Inc. (the "Company"), we enclose the Company's request for acceleration of the above-referenced Registration Statements to 4:00 p.m., Eastern time, on Monday, June 14, 2021, or as soon as possible thereafter.

Please advise the undersigned of the effectiveness of the Registration Statements.

Very truly yours,

/s/ Spencer G. Feldman  
Spencer G. Feldmancc: Mr. Stephan Jackman  
Henry C.W. Nisser, Esq.

O L S H A N F R O M E W O L O S K Y L L P

WWW.OLSHANLAW.COM

**ALZAMEND NEURO, INC.**  
3802 Spectrum Boulevard, Suite 112C  
Tampa, Florida 33612

June 10, 2021

U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549Attention: Abby Adams and Tim Buchmiller  
Division of Corporation Finance,  
Office of Life SciencesRe: Alzamend Neuro, Inc.  
Registration Statement on Form S-1 (No. 333-255955)  
Registration Statement on Form 8-A (No. 001- )

Ladies and Gentlemen:

Alzamend Neuro, Inc. hereby requests that the effectiveness of the above-referenced Registration Statements be accelerated so that they will become effective at 4:00 p.m., Eastern time, on Monday, June 14, 2021, or as soon as possible thereafter.

Very truly yours,

ALZAMEND NEURO, INC.

By: /s/ Stephan Jackman  
Stephan Jackman  
Chief Executive Officer

